Since HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. Peptide inhibitors of NS3 were developed by selective amino acid replacement of six leader sequences, corresponding to regions of HCV polyprotein that are cleaved by NS3. The large numbers of potential 14-mer and 16-mer peptide inhibitors thus obtained were tested against NS3 using the fluorescent probe RETS1 and peptide cofactor SVVIVGRIILSGRA from NS4A protein. This afforded several peptide inhibitors with an IC 50 of around 2 µM. These peptides may be good leading compounds for the development of peptidomimetics to control HCV replication in the treatment of chronic hepatitis C.
Hepatitis C virus (HCV) is a highly prevalent virus. Indeed, it has been estimated that around 170 million people, or 3% of the global population, are infected worldwide (3) (WHO, 1997) . HCV infection leads to chronic hepatitis in around 80-95% of cases (Zoulim et al., 2003) . Chronic HCV slowly evolves to cirrhosis. In studies with a 10-20 year follow-up, cirrhosis developed in 20-30% of the patients, 1-5% of whom may develop liver cancer during the next 10 years (Leyssen et al., 2000) . HCV is a positivestranded RNA virus from the Flaviviridae; its genome is translated into a polyprotein precursor of around 3000 amino acids (Takamizawa et al., 1991 , Tanaka et al., 1992 which is cleaved into several proteins by host and viral proteases (Houghton et al., 1991) . This leads to structural (C, E1, E2) and non-structural (NS2, NS3, NS4A, NS4B, NS5A, NS5B) proteins (Grakoui et al., 1993a , Grakoui et al., 1993c as well as p7, a non-structural protein that forms an ion channel (Pavlovic et al., 2003 , Griffin et al., 2003 , Carrere-Kremer et al., 2002 . Host signal peptidases are responsible for the cleavages leading to E1, E2 and NS2 proteins (Lin et al., 1994 , Mizushima et al., 1994 whereas non-structural proteins are liberated by the action of two proteases encoded by the region NS2-NS3 of the genome.
The first of these proteases is a metalloproteinase named NS2 which is responsible for the cleavage between NS2 and NS3 (Grakoui et al., 1993b , Hijikata et al., 1993a whereas the remaining sites of the non-structural region are cleaved by NS3, a serine-protease encompassed by amino acids 1049 to 1215 of HCV polyprotein (Shoji et al., 1995 , Hahm et al., 1995 , Eckart et al., 1993 . The crystal structure of NS3 is now available (Kim et al., 1996 , Love et al., 1996 . The cleavage products afforded by NS3 are NS3, NS4A, NS4B, NS5A and NS5B (Bartenschlager et al., 1994 , Grakoui et al., 1993a , Hijikata et al., 1993b . The C-terminal end of NS4A protein is very important for the efficient cleavage of NS3/4A and NS4B/5A sites and to enhance the efficiency of cleavage of site NS5A/5B by NS3 , Bartenschlager et al., 1994 , Failla et al., 1994 . Indeed, NS3 is activated through its interaction with the C-terminal end of NS4A, the sequence SVVIVGRIIL being the minimal domain of NS4A that is able to activate NS3 (Tomei et al., 1996) .
Transfection of NIH 3T3 cells with an expression vector containing cDNA for the 5′-, but not the 3′-, half sequence of the HCV genome rapidly proliferated and formed tumours in nude mice, suggesting that the 5′-half encoding NS3 seems to be associated with the development of hepatocellular carcinoma (Sakamuro et al., 1995) . NS3 is essential for the correct processing of HCV polyprotein and hence for viral assembly (Krausslich et al., 1989) . Moreover, NS3 has been reported to block the phosphorylation and effector action of interferon regulatory factor-3 (IRF-3) (Foy et al., 2003) . For all these reasons, NS3 is a target of choice in the treatment of chronic hepatitis C. At present, the only accepted therapies are based on the use of interferon alpha (IFN-α) alone or in combination with ribavirin. The efficacy of IFN-α alone is poor; less that 50% of patients respond to treatment and an important proportion of them relapse after IFN-α withdrawal Introduction (Camps et al., 1994) . This efficacy can be enhanced by combining IFN-α with ribavirin (McHutchison et al., 2001) , especially polyethylene glycol IFN-α (PEG-IFNα) and ribavirin (Manns et al., 2001) . Although these combinations increase efficacy, an important proportion of patients fail to respond. This finding has prompted several groups to develop inhibitors of HCV protease NS3. Thus, the following types of inhibitors have been described: compounds derived from thiazolidine (Sudo et al., 1997) , acetylated peptides derived from the NS5A/5B region (Llinas-Brunet et al., 1998) , aldehyde and boric acid modified peptides derived from NS4A/4B (Attwood et al., 1999) , ketoamide-modified peptides from the NS4A/B (Bennett et al., 2001) , glycine α-ketoamide derived compounds (Han et al., 2003) , halogenated benzanilide type compounds (Kakiuchi et al., 1998) , 3-amino bicyclic pyrazinones (Zhang et al., 2003) and bicyclic pyrimidinone-based compounds (Glunz et al., 2003) . Among the most active inhibitors of NS3 are those reported by Ingalinella et al. (Ingallinella et al., 1998) , who derived peptidomimetics from the regions NS4A/4B and NS3/NS4A (Ingallinella et al., 2000) respectively. These compounds inhibited 10 nM protease or 0.15 nM protease with an IC 50 of 1.5 nM and 0.2 nM, respectively.
We describe below the engineering of HCV protease peptide inhibitors by selective amino acid replacement in the sequence of regions from the HCV polyprotein precursor that are cleaved by the protease. These inhibitors may hopefully, at a later stage, lead to the development of efficient peptidomimetics for the inhibition of this protease and, concomitantly, of HCV replication in HCV chronically-infected patients. Alternatively, these peptide inhibitors might be administered as such, or by using recombinant viruses expressing them.
Materials and methods

Peptides
Peptides were synthesized by Merrifield's solid-phase method (Merrifield, 1963) using the Fmoc alternative (Atherton et al., 1989) . Peptides were analysed by HPLC. Since their purity was usually well above 70%, they were used without further purification. Peptides were kept at -80°C as freeze-dried powders before use.
Potential peptide inhibitors were synthesized as single or multiple amino acid replacements in the sequence of six leading peptides (LP1 to LP6, shown in italics in Table 1 ) derived from regions of the polyprotein that are cleaved by HCV protease: NS3/NS4A (LP2, LP4), NS4B/NS5A (LP3), NS4A/NS4B (LP5) and NS5A/NS5B (LP1, LP6). Modifications of leading peptides were decided based on the following criteria: (i) single or multiple point modifications were undertaken to keep the binding of peptides while preventing their hydrolysis, (ii) multiple replacements by K (and in a few cases by D) were made to enhance solubility of peptides, (iii) multiple replacements by F were carried out based on preliminary results obtained following single replacements by F, and (iv) one or both amino acids from the scissile bond were replaced in an attempt to prevent the peptides' hydrolysis.
Thus, we carried out systematic replacements at different positions of LP2 with A, L, F, G, T, P, E and K, which are amino acids representative of different families. We selected these amino acids for the following reasons: E and K have charged natures that tend to give strong interactions in proteins; F because aromatic amino acids tend to participate in strong hydrophobic interactions (Singh, 1992) ; G, P and A because of their small size, which might help the accommodation of inhibitor peptides to the protease's cleft; G and P might confer flexibility or change the orientation of the peptides, respectively; L is an example of hydrophobic aliphatic amino acid and T is an example of noncharged hydrophilic amino acid. C was replaced by S in LP1, because it is the isoster of C. Also, W was replaced by Y, F or H to avoid problems of synthesis associated with W. With the aim of enhancing the solubility of peptides, we studied the effect of adding groups of K, both at Nterminal and C-terminal ends of peptides. Similarly, D or E were introduced in some peptides.
Cloning of NS3, NS3-6K and NS3-8K
HCV RNA was extracted from the serum of a patient with chronic hepatitis not submitted to IFN-α therapy. The cDNA coding for the region amino acids 1-181 from the HCV NS3 protease was obtained by RT PCR and expressed using the vectors pET14b and pET32a+ (Novagen Inc., Madison, Wis., USA). The plasmids obtained (pETNS3, pETNS3-6K and pETNS3-8K) were checked by digestion and DNA sequencing. The nucleotide and amino acid sequences can be provided by the authors on request. Plasmids were used to transform Escherichia (E.) coli BL21(DE3) to express NS3, NS3-6K and NS3-8K. Protease NS3 corresponds to amino acids 1-181 from NS3 protein whereas NS3-6K contains six additional lysines at its C-terminal end. For example, NS3-8K, besides the extra 8 lysines at its C-terminal end and a few other extra amino acids, contains a region of around 100 amino acids called TRX protein at the N-terminal end which has been shown to confer solubility to proteins favouring expression in bacteria in the soluble fraction (LaVallie et al., 1993) .
Expression of NS3, NS3-6K and NS3-8K
Proteases NS3, NS3-6K and NS3-8K were expressed in identical manner. Clones were grown at 37°C in LBampicillin until an optical density of 0.6 at 600 nm. At this point, isopropyl-D(b)-thiogalactopyranoside (IPTG) was added to a final concentration of 0.4 mM and cultured for 3 h. Cultures were centrifuged at 10000×g for 10 min and the pellets kept at -80°C until further use. Bacteria from these pellets were lysed using a French press (1500 psi) followed by centrifugation at 10000×g for 10 min. Pellets were resuspended in guanidine hydrochloride (5 M) and left standing for 1.5 h. Following centrifugation at 10000×g for 15 min, supernatants were filtered through 0.22 µm filters. Proteases from the filtrates were purified by affinity chromatography based on the interaction between Ni 2+ ions bound to the stationary phase and a group of His residues that were engineered to be part of the sequence of the proteases. For this purpose we used a 5 ml column of IMAC HiTrap  Chelating Sheparose Fast Flow (Amersham Biosciences, Uppsala, Sweden) and, following the manufacturer's instructions, washed with 60 mM imidazol buffer and the proteases eluted with 400 mM imidazol. Eluates were monitored by SDS-PAGE. The main peak containing the protease was concentrated using a centricon YM-10000 tube (Millipore Corp., Bedford, Mass., USA.). Concentrated solutions were then dialysed against 50 mM MES pH 5,5, 50 mM NaCl, 2 mM DTT, 8 M urea buffer. Proteases were activated by diluting aliquots from these dyalisates in activation-assay buffer (HEPES 50 mM pH 7,5, Mg SO 4 10 mM, Glycerol 50%, DTT 2 mM, CHAPS 0,1%). Co-factor peptide SVVIVGRIILSGRA was then added to a final concentration of 10.5 µM, and incubated at 4°C for 1.5 h. This activation buffer is a modification of that previously described by Steinkühler et al. (Steinkuhler et al., 1996a , Steinkuhler et al., 1996b . Because these proteases were engineered to encompass a group of histidines, their SDS-PAGE bands could be identified by Western blot analysis using a commercial anti-His antibody (data not shown).
NS3-6K inhibition assay
The degree of NS3-6K inhibition by peptides was measured as follows. Concentrated solutions (1 mg/ml) of potential peptide inhibitors were diluted in activation-assay buffer or dimethyl sulphoxide, in such a way that 25 µl of solution contained the desired amount of peptide to be tested. This solution was added to the wells of a 96-well black plate, followed by 100 µl of activation-assay buffer containing 10.5 µM co-factor peptide and the desired amount of total protease concentration: 50 nM to 300 nM as estimated by the Bradford assay (Bradford, 1976) and 25 µl of 6 µM substrate (RET S1) AC-Asp-Glu-Asp(EDANS)-Glu-Glu-ABU-y-[COOH]Ala-Ser-Lys(DABCYL)-NH 2 (Anaspec Inc., San José, Calif., USA) (Taliani et al., 1996) . The time course of hydrolysis was followed during 1 h using a Polastar Galaxy (BMH Labtechnologies GMBH, Offenburg, Germany) fluorimeter. Samples were excited at 340 nm and fluorescence measured at 510 nm. Wells without protease, but containing substrate and co-factor peptide, were used as controls. In all inhibition experiments, the rate of hydrolysis was linear within the first hour. Thus, the slope of these hydrolysis was used to estimate the degree of inhibition according to the formula: Inhibition (%)=I=[1-(Slope1-Slope2)/Slope3]×100. Where: Slope 1 is the slope of the substrate's hydrolysis (4 µM) in the presence of protease (50 nM), cofactor peptide (7 µM), and the concentration of inhibitor peptide tested. Slope 2 is the slope corresponding to a sample containing only substrate (4 µM) in activation-assay buffer. Slope 3 is the value obtained using the same solution as Slope 1, but without inhibitor peptide.
Results
Expression and selection of a protease from HCV With the aim of obtaining a protease from HCV that was expressed in a soluble fraction in E. coli, proteases NS3, NS3-6K and NS3-8K were cloned as described in Methods. Comparison of the predicted amino acid sequence of NS3 and NS3-6K with representative sequences from HCV genotypes 1a, 1b, 2a, 2b and 3b showed that the sequence corresponded to genotype 1b (data not shown). Unfortunately, none of the three proteases was expressed in a soluble fraction but rather accumulated in inclusion bodies. Insoluble proteases were extracted from these bodies and purified by affinity chromatography as described in Methods. In Figure 1 , the SDS-PAGE analysis shows the protein composition of the soluble and insoluble fractions from the expression of NS3, as well as of purified NS3, NS3-6K and NS3-8K. Purified proteases show a high degree of purity and the expected molecular weight. 
EDCSTPSSGSFLDR 0 *Potential peptide inhibitors were synthesized as single or multiple amino acid replacements in the sequence of six leading peptides (LP1 to LP6) derived from regions of the polyprotein that are cleaved by HCV protease (see Materials and methods). Amino acid replacements are shown in bold and potential scissile bonds are underlined. Purified proteases were activated as described in Methods and tested at 300 nM (total protein concentration) against fluorescent substrate RETS1 (4 µM) in the presence of co-factor peptide SVVIVGRIILSGRA (4 µM) from NS4A. Since NS3-6K was found to be more active than NS3-8K and NS3 (Figure 2) , the remaining experiments were carried out using NS3-6K. The rate of hydrolysis of RETS1 was studied at 0 nM, 50 nM, 100 nM, 150 nM and 300 nM of NS3-6K (Figure 3 ). Based on the results of this experiment, we tested the inhibitory capacity of peptides against 50 nM of NS3-6K throughout this work.
Inhibition of NS3-6K with synthetic peptides
We attempted to develop peptide inhibitors of NS3 by synthesizing the peptides from Table 1 . These peptides correspond mainly to modifications around leading peptide LP2 and a few exploratory modifications around LP1, LP3 to LP6. Peptides LP1 to LP6 are related to regions of HCV polyprotein cleaved by NS3. They were selected as leader sequences because previous experiments carried out in our laboratory, using a large radioactive protein substrate encompassing the region NS5A/NS5B of HCV polyprotein, had shown that LP2 (and to a lesser extent LP1 and LP3-LP6) had some inhibitory capacity on NS3 (Gonzalez-Navarro, 1997). All peptides (Table 1) were tested by duplicate at the concentration of 3 µM of peptide and 50 nM of NS3-6K. In order to assess the IC 50 of the best peptide inhibitors, the 25 inhibitor peptides from Table 1 with higher activity were again tested by sextuplicate at three peptide concentrations (1 µM, 3 µM and 10 µM) and 50 nM of NS3-6K. In all experiments, the inhibitors' activity was measured in parallel with a commercial inhibitor from Bachem (Bachem, Bubendorf, Switzerland) developed by Ingallinella et al. (Ingallinella et al., 1998) . The inhibitors that had an IC 50 below 10 µM are shown in Table 2 .
Discussion
Our strategy to design peptide inhibitors is based on the hypothesis that a sequence from a region of the polyprotein cleaved by NS3 can be transformed into an efficient inhibitor by selective amino acid replacements in this sequence, in particular by changing those residues that are near or correspond to residues that form the scissile bond. 
AcDEVVCC 0 The control corresponds to the hydrolysis of substrate in the absence of protease. The slopes shown were taken from the corresponding rates of hydrolysis at 30°C of fluorescent substrate RETS1 (4 µM), cofactor peptide SVVIVGRIILSGRA (7 µM) and protease (300 µM).
Since during viral assembly, several regions of the HCV polyprotein are hydrolysed by the viral protease, we synthesised peptides derived from six leader peptides (LP1 to LP6) that are representative of these regions (Table 1 ). In general, simultaneous replacement of several amino acids from the C-terminal end of LP2 by K had a deleterious effect on the inhibitor capacity of peptides. This suggests that inhibitor peptides require a hydrophobic Cterminus, or at least one that is not positively charged.
Indeed, most of the best inhibitor peptides had an hydrophobic C-terminus, although in a few cases the presence of E or D was accepted (Table 2 ). In contrast, the presence of a group of four Ks at the N-terminus was tolerated by the intermediate inhibitors, although the best inhibitors contained D and E at this end.
In a large group of peptides derived from LP2 (peptides P49 to P114), all containing four K at the N-terminal end and Y at position 10, we carried out single amino acid replacements in their sequence. It was found that substitutions by A and F had the least deleterious effects on the inhibition capacity of modified peptides. In contrast, substitutions by P and, to a lesser extent, by G, had the most pronounced effect in reducing their inhibitory potential. Since substitutions by F in many positions enhanced the activity of peptides, we also tested several simultaneous replacements by F. This did not have an additive effect; on the contrary, in the majority of cases the activity of multi- Inhibition of NS3-6K protease (50 nM) was measured at 30ºC in the presence of co-factor peptide SVVIVGRIILSGRA (7 µM) and fluorescent substrate RETS1 (4 µM) at three concentrations (1 µM, 3 µM, 10 µM) of inhibitor peptides. *An inhibitor commercialized by Bachem (Bachem, Bubendorf, Switzerland) and developed by Ingallinella et al. (Ingallinella et al., 1998) , against which the activities of peptides are compared.
Time ( Hydrolysis was carried out at 30°C in the presence of cofactor peptide SVVIVGRIILSGRA (7 µM) and RETS1 (4 µM). The slopes at protease concentrations 300 nM, 150 nM, 100 nM, 50 nM and 0 nM were respectively 3655 ±378, 3338 ±352, 1707 ±93, 890 ±102 and 58.2 ±25. The concentration of protease corresponds to total protein concentration as estimated using the Bradford assay (Bradford, 1976) . See Materials and methods. substituted peptides was much lower than that of peptides substituted by F at position 7, which was the most active position for mono-substituted peptides by F. This clearly shows that the effect of substitutions at any given position cannot be easily predicted, probably because each replacement has an effect on the global structure of the peptide, preventing an additive effect due to the potential contribution from a substitution in another position. Thus, the effect on activity of a given substitution can only be taken as a hint to design possible inhibitors.
Our results clearly demonstrate that peptides can indeed block the activity of NS3, a result in contrast with the reported lack of activity of unconstrained peptide CWHACRRVC which was only active when presented by phage-displayed repertoires of minibodies ('minimized' antibody-like proteins) (Dimasi et al., 1997) . It is interesting to note that the active peptide loops displayed by the phage reported by Dimasi et al. contain in most cases a C inside the loop in addition to the two Cs at the N-terminal and C-terminal ends of the peptides. A well-exposed C may have a high tendency to form disulphide bridges with other Cs from the same peptide or from other peptides. This may explain the lack of activity of free peptide CWHACRRVC by dimer or even polymer formation. However, similar reasoning may suggest that the activity of these C-containing minibodies might be due to disulphide bridge formation between these Cs and a C from NS3, and not to a non-covalent interaction with the NS3 cleft. Of all the best inhibitor peptides of the present study, only P190 contains C (Table 2) . Thus, the activity of the majority of these inhibitors is not related to a potential disulphide bridge formation between the inhibitor and protease.
In order to compare the activity of our peptides with some of the best inhibitors reported in the literature, we purchased the commercially available peptidomimetics Ac-Asp-D-Gla-Leu-Ile-Cha-Cys-OH (Bachem) developed by Ingallinella et al. (Ingallinella et al., 1998) , which was reported to have an IC 50 of 1.5 nM at 10 nM protease. When we tested the activity of this peptidomimetic using 50 nM NS3-6K, it was found to have an IC 50 of 1.6 µM which is approximately 1000 fold less active than reported. This drop in activity might be at least partially related to the higher concentration of NS3 protease used in our assay or to differences in buffer composition between both assays. The similarity between the IC 50 of the commercial inhibitor and the best inhibitors from Table 2 suggests that our peptides may have similar potencies to the best reported NS3 inhibitors. However, in order to draw firm conclusions on the relative potency of these inhibitors, their activities should be compared under identical experimental conditions using different types of assays.
With the exception of P189 and P197, which are the fourth and the eleventh best inhibitors listed in Table 2 , the remaining peptides correspond to modifications at position P1 and, in the majority of cases, at both P1 and P1′ of the sequence in the region NS3/4A from HCV polyprotein cleaved by NS3. Most peptides contain an Ala at positions P1 and P1′ replacing the scissile bond Thr-Ser in the region NS3/4A. This was done in order to attempt to prevent hydrolysis of the scissile bond from this region. Although not formally proved, it is tempting to speculate that these modifications may have abolished, or at least diminished, the substrate character of our best peptide inhibitors.
In the present study we have synthesized and tested over 200 potential peptide inhibitors of NS3 protease, mainly around the cleavage region NS3/4A of HCV polyprotein. However, the effect of more substitutions at other cleavage regions remains to be explored. For this reason, our results may serve as guidance for the search of more efficient peptide inhibitors.
It is likely that the direct administration of peptide inhibitors may not be the method of choice because of the limited half life of peptides in vivo. However, once a peptide of high activity is obtained, its sequence may guide the design of peptidomimetics with a higher half life. Alternatively, the peptide inhibitor might be administered using viral vectors, such as defective recombinant adenoviruses expressing the peptide; because of their high tropism for the liver, these would deliver the peptide where it is most needed (Bruna-Romero et al., 1997) . It is hoped that one or both of these two types of NS3 inhibitors might be useful to control HCV replication in chronic hepatitis C.
